CN117442657A - Paris polyphylla or extract thereof, composition and application thereof - Google Patents

Paris polyphylla or extract thereof, composition and application thereof Download PDF

Info

Publication number
CN117442657A
CN117442657A CN202311535311.3A CN202311535311A CN117442657A CN 117442657 A CN117442657 A CN 117442657A CN 202311535311 A CN202311535311 A CN 202311535311A CN 117442657 A CN117442657 A CN 117442657A
Authority
CN
China
Prior art keywords
liver
extract
grass
liver injury
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311535311.3A
Other languages
Chinese (zh)
Inventor
乡世健
李沙沙
陈燕纯
周本杰
曾海燕
吴辉星
龙昌锐
张振华
杨雨渲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seventh Affiliated Hospital Of Sun Yat Sen University Shenzhen
Original Assignee
Seventh Affiliated Hospital Of Sun Yat Sen University Shenzhen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seventh Affiliated Hospital Of Sun Yat Sen University Shenzhen filed Critical Seventh Affiliated Hospital Of Sun Yat Sen University Shenzhen
Priority to CN202311535311.3A priority Critical patent/CN117442657A/en
Publication of CN117442657A publication Critical patent/CN117442657A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The application discloses the use of the Dianthan grass or an extract thereof in the preparation of a medicament or health-care product for treating and/or preventing diseases caused by liver injury and the use of the Dianthan grass or an extract thereof in the preparation of a medicament or health-care product for treating and/or preventing diseases and/or symptoms related to diseases caused by liver injury. The lycopodium clavatum or the extract thereof can effectively relieve hepatomegaly, improve the antioxidant function of the liver and effectively prevent and relieve diseases caused by liver injury. And can effectively relieve abnormal biochemical indexes caused by liver injury and pathological abnormality of liver, and remarkably relieve the progress of acute liver injury.

Description

Paris polyphylla or extract thereof, composition and application thereof
Technical Field
The application relates to the field of traditional Chinese medicine or medicinal chemistry, in particular to an echinacea or an extract thereof, a composition thereof and application thereof.
Background
The liver is a major organ for absorption, distribution, metabolism and elimination of the human body, and plays a key role in glycometabolism, protein metabolism, lipid metabolism, etc. In the factors such as virus infection, bacterial infection, alcohol, drug liver injury, liver ischemia-reperfusion, pathogenic liver injury, etc., the organism can be stimulated to generate excessive high-activity oxygen free radicals, induce oxidative stress, induce inflammatory reaction, and further cause pathological changes such as hepatocyte apoptosis, hepatitis, liver fibrosis, liver injury, etc.
With the rapid development of medicine technology, many medicines for treating liver injury have been researched and reported, and mainly comprise Chinese herbal medicines, biological medicines, chemical medicines, trace elements and the like. However, some studies have shown that some drugs against liver injury also inevitably produce biotoxicity. It can be seen that prevention and treatment of liver injury is still a serious problem at present.
The traditional Chinese medicine is the treasure of the traditional Chinese medicine in China, and a plurality of traditional Chinese medicines and traditional Chinese medicine components with the effects of clearing heat and detoxicating, promoting diuresis and removing jaundice, promoting blood circulation and removing blood stasis, soothing liver and regulating qi and the like can be used for directly treating liver injury, and no obvious toxic or side effect is generated, so that the research and development of the medicines have important practical significance for treating clinical liver injury.
Disclosure of Invention
The protection effect of the liver injury of the Dianchin grass is not disclosed at present. The application finds that the stonecrop herb or the extract thereof can be used for preventing and treating diseases caused by liver injury through a plurality of experiments.
Specifically, the application adopts the following technical scheme,
1. use of the herb or extract thereof for the manufacture of a medicament or health product for the treatment and/or prevention of diseases caused by liver damage.
2. Use of the herb or an extract thereof for the manufacture of a medicament or a health product for the treatment and/or prevention of diseases and/or disorders associated with diseases caused by liver damage.
3. The use according to claim 1 or 2, wherein the disease caused by liver injury is selected from any one of acute liver injury, chronic liver injury, liver fibrosis, liver cirrhosis, and liver cancer.
4. The use of item 1 or 2, wherein the cause of the liver injury is selected from any one of trauma, drug, alcohol, chemical toxic substance, virus or autoimmunity.
5. The use of item 1 or 2, wherein the medicament or health product is for use in a mammal.
6. The use according to item 1 or 2, wherein the medicament or healthcare product is for use in humans, preferably the medicament or healthcare product is administered in a single dose corresponding to 15g to 120g of life Dan Chancao, more preferably 30g to 60g of life Dan Chancao.
7. The use of item 1 or 2, wherein the grass extract is an aqueous or alcoholic grass extract.
8. The use of item 7, wherein said aqueous extract of the grass of the Eichhornia crassipes is extracted by,
crushing: pulverizing the herb of Chan into coarse powder;
water heating reflux extraction: adding pure water into the coarse powder, reflux-extracting, filtering, adding pure water again, reflux-extracting again, filtering, and combining the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the aqueous extract of the Dianthan grass.
9. The use of item 7, wherein said alcohol extract of the stonecrop herb is extracted by,
crushing: pulverizing the herb of Chan into coarse powder;
heating and reflux extracting ethanol: adding ethanol into the coarse powder, reflux-extracting, filtering, adding ethanol again, reflux-extracting again, filtering, and mixing the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the Dianthan alcohol extract.
10. The use according to any one of items 1 to 3, wherein the medicament or health product further comprises one or more other active substances.
11. A composition for treating and/or preventing a disease caused by liver injury, wherein the composition comprises Dan Chan grass or an extract thereof as the only active ingredient.
12. The composition of item 11, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients, or further comprises one or more additional active substances.
13. The composition of item 11 or 12, wherein the disease caused by liver injury is a disease related to item 3 or 4.
14. A composition according to item 11 or 12, wherein the grass extract is a grass extract according to any one of items 7 to 9.
Effects of the invention
The lycopodium clavatum or the extract thereof can effectively relieve hepatomegaly, improve the antioxidant function of the liver and effectively prevent and relieve diseases caused by liver injury. And can effectively relieve abnormal biochemical indexes caused by liver injury and pathological abnormality of liver, and remarkably relieve the progress of acute liver injury.
In addition, the preparation method of the grass extract of the grass is simple, low in preparation cost, meets the industrial production requirements, has practical significance and application value in developing medicines or products, and improves the utilization rate of the grass to a certain extent.
Drawings
The drawings are included to provide a better understanding of the present application and are not to be construed as unduly limiting the present application. Wherein:
FIG. 1 is a schematic view ofCCl 4 Each group of mice in the liver injury model has liver tissue pathological sections;
changes in serum alanine Aminotransferase (ALT) (n=5) in mice of different groups of fig. 2;
fig. 3 shows the variation of serum aspartate Aminotransferase (AST) (n=5) for different groups of mice;
fig. 4 is a graph of the change in glutathione peroxidase (GSH) of liver tissue of different groups of mice (n=5);
fig. 5 shows changes in oxide dismutase (SOD) of liver tissue of different groups of mice (n=5);
fig. 6 shows the changes in Catalase (CAT) of liver tissue of different groups of mice (n=5).
( P <0.05 compared to model control; * P <0.001; * P <0.0005; * P <0.0001 )
Detailed Description
Exemplary embodiments of the present application are described below, including various details of embodiments of the present application to facilitate understanding, which should be considered as merely exemplary. Accordingly, one of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
The present application provides the use of the herb or an extract thereof in the manufacture of a medicament or a health product for the treatment and/or prevention of a disease caused by liver damage.
The application also provides the use of the herb or an extract thereof for preparing a medicament or a health-care product for treating and/or preventing diseases and/or symptoms related to diseases caused by liver injury.
Dan Chancao (Herb of Dindygulen Peperomia) the medicinal part is whole herb of Piperaceae plant Dan Chancao Peperomia dindigulensis Miq. And is mainly distributed in Fujian, taiwan, guangxi, guangdong, yunnan, guizhou, etc. The aliases are called fire injury leaf, pepper herb and blood-dispelling gall; it is cool in nature, bland in taste and slightly bitter. It enters lung meridian, spleen meridian, liver meridian and kidney meridian. It is mainly used for clearing away heat and toxic materials, relieving swelling, removing blood stasis, relieving pain, and promoting diuresis. Belongs to the heat-clearing and toxicity-removing herbs classified under heat-clearing herbs. It is used for treating gastric cancer, esophageal carcinoma, lung cancer, breast cancer, traumatic injury, burn, carbuncle, sore, furuncle, nephritis, edema, pulmonary tuberculosis, asthma, tracheobronchitis, and cough due to lung heat.
The liver injury mainly refers to the damage of liver cells, abnormal liver structure and function, and the liver injury can stimulate an organism to generate excessive high-activity oxygen free radicals, induce oxidative stress, trigger inflammatory reaction, cause the damage and apoptosis of the liver cells and release excessive transaminase into blood so as to influence normal liver function. If not prevented or treated in time, a series of complications may be induced or the development of other diseases may be promoted.
The innovative discovery of this application that the herb or extract thereof has therapeutic or prophylactic effects on diseases caused by liver injury.
The liver injury is caused by a plurality of reasons, mainly including drug poisoning, virus infection, excessive alcohol intake, immune response, chemical toxic substances in contact environment, radiation injury and the like. The use of the herb or extract thereof of the present application for the treatment or prevention of diseases caused by liver injury is not limited to cause of liver injury, and any liver injury, such as liver cell injury, abnormal liver structure and function, is within the scope of the present application, and in a preferred embodiment, the liver injury is caused by alcohol, virus, drug and chemical toxic substances.
The specific type of the disease caused by liver injury is not limited in the present application, and any disease caused by liver injury is within the scope of protection of the present application, including but not limited to acute liver injury, chronic liver injury, liver fibrosis, liver cirrhosis, hepatitis, liver cancer, fatty liver, liver failure, etc., such as liver injury, fatty liver, hepatitis, liver cirrhosis, liver failure, etc., caused by factors such as alcohol. In a preferred embodiment, the disease is acute liver injury or chronic liver injury.
The diseases and/or symptoms related to the diseases caused by the liver injury refer to other diseases or symptoms caused by the liver injury, and the diseases or symptoms can be relieved or eliminated due to the liver injury or the liver injury after treatment.
The term "preventing and/or treating" means that treatment, prevention, alleviation and/or alleviation of a disease or a disorder described herein, in a subject, can be effected.
The term "disease and/or disorder" refers to a physical state of the subject that is associated with the disease and/or disorder described herein.
The medicament or health product may be for use in a patient or other animal receiving a medicament or health product of the present application for treating, preventing, alleviating and/or alleviating a disease or condition described herein, and in a preferred embodiment the medicament or health product is for use in a mammal. Including but not limited to humans, cows, horses, sheep, pigs, goats, rabbits, cats, dogs, mice, and any other mammal having a liver and which may be damaged.
In a preferred embodiment, the medicament or health product is for use in humans.
The amount of drug or health product administered in the present application depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight and individual response of the patient or animal, the route and frequency of administration, etc. The above-mentioned doses may be administered in a single dosage form or divided into several, for example two, three or four dosage forms. The dosage level will be selected based on the particular route of administration, the severity of the condition being treated, the condition and past medical history of the patient to be treated, and the like.
It will be appreciated that the total daily amount of the medicament or health care product of the present application must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the particular therapeutically effective dose level will depend on a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; age, weight, general health, sex and diet of the patient; time of administration, route of administration, and rate of excretion; duration of treatment; a drug used in combination or simultaneously; and similar factors well known in the medical arts. For example, it is common in the art to administer doses that begin at levels below that required to achieve the desired therapeutic effect and gradually increase until the desired effect is achieved.
In a further preferred embodiment, the medicament or health care product is administered in a single dosage form, i.e. in a single dosage form, in a further preferred embodiment the single dosage administered corresponds to 15g to 150g of the product Dan Chancao, for example 16g, 17g, 18g, 19g, 20g, 30g, 40g, 50g, 60g, 70g, 80g, 90g, 100g, 110g, 120g, 130g, 140g, further preferred 30g to 60g of the product Dan Chancao. It will be appreciated by those skilled in the art that, typically, the weight of a person is 60kg, and if the weight of the person is not 60kg, the conversion may be made in accordance with this standard.
The medicament or health care product of the present application may be administered in unit dosage form by the enteral or parenteral route, such as oral, intramuscular, subcutaneous, nasal, oral mucosal, dermal, peritoneal or rectal, etc. For example, tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injection and the like. Can be common preparation, slow release preparation, controlled release preparation and various microparticle administration systems.
The Parabarium songaricum extract can be a water extract or an alcohol extract of Parabarium songaricum, or a mixture of water-alcohol extracts.
The herb of the stone Chan and any part thereof can be used to prepare Dan Chan herb extracts, such as roots, stems, leaves, flowers, etc.
The terms "medicinal material", "Chinese medicine" etc. may be a material of natural origin (e.g. mineral or plant) which may have, in addition to a pharmacological active effect as a treatment, an effect for preventing, regulating physiological functions, but may of course have other physiological effects not listed herein.
The following "Dan Chan herbs" are whole grass of the stonecrop herb and/or any part thereof.
The method of extraction of the aqueous extract of the Dianthan grass may use any of the methods of water extraction known in the art, and in a preferred embodiment, the present application employs the following methods to prepare the aqueous extract of Dan Chancao:
crushing: pulverizing the herb of Chan into coarse powder;
water heating reflux extraction: adding pure water into the coarse powder, reflux-extracting, filtering, adding pure water again, reflux-extracting again, filtering, and combining the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the aqueous extract of the Dianthan grass.
The water may be any form of water known in the art, such as purified water, deionized water, secondary water, and the like.
The number of reflux extractions is not limited in this application, and may be one, two, three, four or more times.
The method of extraction of the alcohol extract of the Chaetoceros may use any of the water extraction methods known in the art, and in a preferred embodiment, the present application employs the following methods to prepare the Dan Chancao alcohol extract:
crushing: pulverizing the herb of Chan into coarse powder;
heating and reflux extracting ethanol: adding ethanol into the coarse powder, reflux-extracting, filtering, adding ethanol again, reflux-extracting again, filtering, and mixing the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the Dianthan alcohol extract.
Wherein ethanol may be any other common alcohol in the art, such as methanol, propanol, butanol, etc.
The number of reflux extractions is not limited in this application, and may be one, two, three, four or more times.
In a preferred embodiment, the medicament or health product optionally further comprises a pharmaceutically acceptable carrier or excipient. Including, but not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil and the like. In addition to the above components, the pharmaceutical or health product of the present application may contain lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preserving agents, and the like.
In a preferred embodiment, the medicament or health product for the treatment and/or prophylaxis of diseases caused by liver damage in the present application may further comprise one or more additional active substances. The other active substances refer to substances which have activity and produce a certain function except for the common stonecrop herb or the extract thereof, the active substances can be active substances for treating or preventing diseases caused by liver injury, can be active substances for assisting in treating or preventing diseases caused by liver injury, can also be active substances for not treating diseases caused by liver injury, but can have positive effects or functions at other convenience, and the active substances can be one or more of medlar, astragalus, mulberry leaf, artemisia capillaris, coix seed, red sage root, hawthorn, liquorice and the like or the extract thereof, and the other active substances can be crude drugs or the extracts thereof (such as water extracts, alcohol extracts or alcohol-water mixtures).
The present application further provides a composition for treating and/or preventing a disease caused by liver injury, wherein the composition comprises Dan Chan grass or an extract thereof as the only active ingredient.
The term "composition" is intended to include products comprising the specified amounts of each specified ingredient as well as any product that results, directly or indirectly, from combinations of the specified amounts of each specified ingredient.
In a preferred mode, the composition further comprises one or more pharmaceutically acceptable carriers or excipients. The one or more pharmaceutically acceptable carriers or excipients are as described in any one of the above.
In a preferred manner, the composition further comprises one or more additional active substances. The one or more other active substances are other active substances as described in any one of the above.
The disease caused by liver injury is a disease caused by liver injury as described in any one of the above.
The Dianthus sonchifolius extract is any one of the above-mentioned Dianthus sonchifolius extracts.
The composition according to any one of the present application may be in the form of an injection, an oral liquid, a capsule, a tablet, a granule, or an extract remixed dosage form.
The composition according to any of the present application may be administered in a single dosage form by the enteral or parenteral route, such as oral, intramuscular, subcutaneous, nasal, oral mucosal, dermal, peritoneal or rectal, etc. For example, tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injection and the like. Can be common preparation, slow release preparation, controlled release preparation and various microparticle administration systems.
The dosage of the composition according to any one of the present application can be converted with reference to the dosage of the herb or extract thereof as described above.
In the present application, the terms "alanine aminotransferase (ALT, alanine aminotransferase)" and "aspartate aminotransferase (AST, aspartate aminotransferase)" are enzymes whose values in blood increase when the liver is damaged, respectively, that is, enzymes utilizing such characteristics as an index of liver function.
In the present application, the term "glutathione peroxidase (GSH), which reduces toxic hydrogen peroxide to a non-toxic hydroxyl compound, thereby protecting a biological membrane from active oxygen, maintaining normal functions of cells, and" superoxide dismutase (SOD, superoxide dismutase) "is an enzyme capable of catalyzing the conversion of superoxide to oxygen and hydrogen peroxide by disproportionation, both of which are enzymes whose content level changes in the liver when the liver is damaged, i.e., enzymes that use this property as antioxidant activity of the liver.
"Catalase" catalyzes H 2 O 2 Decomposition to produce H 2 O and O 2 By scavenging H 2 O 2 An enzyme exhibiting antioxidant activity as an index of liver function.
The application proves that the application of the grass or the extract thereof in preparing liver protection products can effectively relieve CCl 4 The hepatomegaly caused by the method improves the antioxidant function of the liver, and effectively prevents and relieves CCl 4 And the liver is damaged.
The drugs commonly used in the prior art for treatment or prevention, such as the positive drug DDB used in the application, have the advantages that transaminase can be obviously and rapidly reduced, however, the change of liver histology is not obvious, the effects of anti-inflammatory and protecting liver cells are actually poor, other drugs, such as silymarin, have low bioavailability, can be directly absorbed and utilized in intestinal tracts after being taken, have slow application curative effect and relatively long treatment course, and the lycopodium clavatum or the extract thereof has obvious and rapid reduction of transaminase, protects the histology of the liver, can be comprehensively conditioned, and is mild and safe.
Examples
Experimental materials
Test animals: SPF-class male C57BL/6 mice, body weight (22.+ -.2) g,8 weeks old. The purchase of Shanghai Baitong Biotechnology Co., ltd., animal license number [ SCXK. Yue 2022-0051];
test drugs and reagents: 95% ethanol (AR), shanghai microphone Biochemical technologies Co., ltd;
carbon tetrachloride (HPLC), shanghai microphone Biochemical technologies Co., ltd;
olive oil (pharmaceutical grade) Shanghai Meilin Biochemical technology Co., ltd, liver function and oxidative stress detection kit, nanjing built biological engineering research all Co., ltd;
example 1 preparation of used stonecrop herb (purchased from Anguo digital chinese medicine);
physiological saline;
glutamic-pyruvic transaminase (AST), glutamic-pyruvic transaminase (ALT), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) kit (all of which are purchased from the scientific and technological company of south kyphosis).
Example 1 preparation of an extract of Paris polyphylla
In the embodiment, the water extraction and the alcohol extraction are respectively carried out on the Dianthan grass, the specific method is as follows,
1.1 Water extraction
(1) Preliminary crushing: pulverizing the herb of Chan into coarse powder.
(2) Extracting pure water and ethanol under heating and reflux: collecting dried Dan Chan herbal coarse powder, reflux-extracting with 8 times of pure water for 1 hr, filtering, adding 8 times of pure water, reflux-extracting for 1 hr, filtering, and mixing the filtrates.
(3) Concentrating the filtrate: concentrating the filtrate under reduced pressure until the relative content of the raw materials is 1g/mL.
1.2 alcohol extraction
(1) Preliminary crushing: pulverizing the herb of Chan into coarse powder.
(2) Extracting with 95% ethanol under reflux: extracting dried Dan Chan herbal coarse powder with 8 times of 95% ethanol under reflux for 1 hr, filtering, adding 8 times of 95% ethanol, extracting under reflux for 1 hr, filtering, and mixing the filtrates.
(3) Concentrating the filtrate: concentrating the filtrate under reduced pressure until the relative content of the raw materials is 1g/mL.
Example 2 experimental methods and results of the action of the extract of the Chaeto lycoris on the acute liver injury of mice induced by carbon tetrachloride.
2.1 Experimental methods
2.1.1 grouping and administration of animals
The test method comprises the following steps: after the animals were fed for 7d, 56C 57BL/6J mice were randomly and equally divided into 7 groups, which were respectively a normal control group, a model control group, a bifendate positive control group, a Dan Chancao water-extraction low-dose and high-dose treatment group, and a Dan Chancao alcohol-extraction low-dose and high-dose group. Each group is fed with common feed, and the feeding period is 1 week. Starting at 1d, normal control group mice and model control group mice are filled with normal saline, the water extraction/alcohol extraction of the lycopodium clavatum is reduced, and high-dose treatment group mice are respectively filled with 3.9g/kg, 7.8g/kg Dan Chancao, and the stomach is continuously filled for 7d.
2.1.2CCl 4 Establishment of acute liver injury model
Within 1h after the last administration, 1% of CCl was subcutaneously injected into each group of mice except the control group 4 Olive oil solution induces acute liver injury in mice.
2.1.3 sample collection and handling
After 16H, killing the mice, taking liver lobules, fixing the liver lobules with 4% formalin solution, embedding paraffin into slices, and observing pathological changes such as hepatocyte necrosis, hepatocyte water sample change, inflammatory cell infiltration and the like under a light microscope after H & E staining; serum and liver are collected and stored at-80 ℃ to be tested.
Statistical analysis: all experimental data were analyzed using Graphpad Prism 9.0 statistical software. p <0.05 is significant for differences and p <0.01 is very significant for differences.
2.2 results
2.2.1 liver pathological section conditions of mice in each group
For normal control group/blank control group (NC), model group (CCl) 4 ) Pathological section of liver tissue of mice, liver tissue H, was performed in groups of bifendate (DDB), dan Chancao water extract high dose group (SCC-S-H), low dose group (SCC-S-L) and Dan Chancao alcohol extract high dose group (SCC-C-H), low dose group (SCC-C-L)&E staining observation is shown in figure 1, the liver lobule structure of a blank control group (NC) is basically maintained normal, liver plates are orderly arranged, liver sinuses are not obviously expanded, interface inflammation is not seen, and liver cells are not obviously necrotized, regenerated and denatured; model group (CCl) 4 ) Slightly disturbed liver lobular cell structure, turbid and swollen liver cells, water sample denaturation can be observed, and modeling is successful; the bifendate group (DDB) can observe little water sample deformation, but is somewhat better than the model group; dan Chancao Water extract high dose group (SCC-S-H), low dose group (SCC-S-L) and Dan Chancao alcohol extract high dose group (SCC-C-H), low dose group (SCC-C-L) andthe model group is improved, especially the water extraction low dose group and the alcohol extraction low dose group, and the liver cells are free from turbidness, water sample denaturation and the like, so that the improvement is obvious.
2.2.2 serum ALT and AST levels in mice of each group
The glutamic-oxaloacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT) were measured in the serum of each group of mice after the completion of the experiment, and the results are shown in fig. 2 and 3.
As can be seen from FIGS. 2 to 3, in the serum of the model control mice, there was a significant increase in glutamic-oxaloacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT) (p<0.01 Indicated CCl) 4 The injection causes the damage of liver cells and the decline of liver functions, and the modeling is successful. The low and high doses of Dan Chancao water and alcohol extracts significantly reduced AST and ALT enzyme activity in serum (p<0.01 Dan Chancao is effective in alleviating CCl 4 The induced liver injury has liver protecting effect.
2.2.3 liver GSH, SOD, CAT levels in mice of groups
Meanwhile, glutathione (GSH), superoxide dismutase (SOD), and Catalase (CAT) in the livers of the mice of each group were measured, and the results are shown in fig. 4 to 6.
As can be seen from FIGS. 4 to 6, glutathione (GSH), superoxide dismutase (SOD) and Catalase (CAT) were significantly reduced in the liver of the mice in the model control group compared with the blank control group (p<0.01 Malondialdehyde (MDA) was significantly elevated, indicating injection of CCl 4 Easily causes oxidation injury of liver cells, and successfully forms the mould. Dan Chancao low water extraction, high dosage and low alcohol extraction, and high dosage can obviously raise SOD, GSH, CAT enzyme activity in liver (p)<0.01 Dan Chancao is effective in alleviating CCl 4 The induced oxidative damage of the liver has an antioxidant protective effect on the liver.
Although described above in connection with the embodiments of the present application, the present application is not limited to the specific embodiments and fields of application described above, which are intended to be illustrative, instructive, and not limiting. Those skilled in the art, having the benefit of this disclosure, may make numerous forms, and equivalents thereof, without departing from the scope of the invention as defined by the claims.

Claims (15)

1. Use of the herb or extract thereof for the manufacture of a medicament or health product for the treatment and/or prevention of diseases caused by liver damage.
2. Use of the herb or an extract thereof for the manufacture of a medicament or a health product for the treatment and/or prevention of diseases and/or disorders associated with diseases caused by liver damage.
3. The use according to claim 1 or 2, wherein the disease caused by liver injury is selected from any one of acute liver injury, chronic liver injury, liver fibrosis, liver cirrhosis, liver cancer.
4. The use of claim 1 or 2, wherein the cause of the liver injury is selected from any one of trauma, drug, alcohol, chemical toxic substance, virus or autoimmunity.
5. The use of claim 1 or 2, wherein the medicament or health product is for use in a mammal.
6. The use according to claim 1 or 2, wherein the single dose of the medicament or healthcare product corresponds to 15g to 120g of raw Dan Chancao.
7. The use of claim 6, wherein the single dose of the medicament or health care product corresponds to 30g to 60g of Dan Chancao.
8. The use of claim 1 or 2, wherein the grass extract is an aqueous or alcoholic grass extract.
9. The use as claimed in claim 8, wherein said aqueous extract of the grass of the Carpesium album is extracted by,
crushing: pulverizing the herb of Chan into coarse powder;
water heating reflux extraction: adding pure water into the coarse powder, reflux-extracting, filtering, adding pure water again, reflux-extracting again, filtering, and combining the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the aqueous extract of the Dianthan grass.
10. The use as claimed in claim 8, wherein said grass alcohol extract is extracted by,
crushing: pulverizing the herb of Chan into coarse powder;
heating and reflux extracting ethanol: adding ethanol into the coarse powder, reflux-extracting, filtering, adding ethanol again, reflux-extracting again, filtering, and mixing the two filtrates;
concentrating the filtrate: concentrating the filtrate under reduced pressure to obtain the Dianthan alcohol extract.
11. A use according to any one of claims 1 to 3 wherein the medicament or health product further comprises one or more other active substances.
12. A composition for treating and/or preventing a disease caused by liver injury, wherein the composition comprises Dan Chan grass or an extract thereof as the only active ingredient.
13. The composition of claim 12, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients, or further comprises one or more other active substances.
14. The composition of claim 12 or 13, wherein the disease caused by liver injury is a disease according to claim 3 or 4.
15. A composition according to claim 12 or 13, wherein the grass extract is a grass extract according to any one of claims 8 to 10.
CN202311535311.3A 2023-11-16 2023-11-16 Paris polyphylla or extract thereof, composition and application thereof Pending CN117442657A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311535311.3A CN117442657A (en) 2023-11-16 2023-11-16 Paris polyphylla or extract thereof, composition and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311535311.3A CN117442657A (en) 2023-11-16 2023-11-16 Paris polyphylla or extract thereof, composition and application thereof

Publications (1)

Publication Number Publication Date
CN117442657A true CN117442657A (en) 2024-01-26

Family

ID=89583572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311535311.3A Pending CN117442657A (en) 2023-11-16 2023-11-16 Paris polyphylla or extract thereof, composition and application thereof

Country Status (1)

Country Link
CN (1) CN117442657A (en)

Similar Documents

Publication Publication Date Title
CN111166734A (en) Use of naphthoquinones to treat pneumonia caused by pathogenic organisms
CN113384647B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury
KR101416453B1 (en) A medicine composition for treating bronchial asthma and preparative method thereof
CN1943707B (en) A Chinese traditional medicinal composition for anti-aging and its preparation method
JPH05186360A (en) Therapeutic agent for allergic disease and production of acanthopanax senticosus extract
RU2651750C2 (en) Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer
CN117442657A (en) Paris polyphylla or extract thereof, composition and application thereof
CN101152379A (en) Traditional Chinese medicine for treating cough and technique of preparing the same
CN117064962B (en) Tung or extract thereof, composition thereof and use thereof
CN117717572A (en) Herba Lycopodii or its extract, its composition and application
KR101086037B1 (en) Preventive and curative extracts from Sophorae Radix for respiratory organ disease
CN115671219B (en) Traditional Chinese medicine composition for treating gout and preparation method and application thereof
CN118286310A (en) Application of nux Prinsepiae or extract and composition thereof in treating and/or preventing liver injury
CN117982557A (en) Use of fermented soya bean ginger or its extract and its composition
CN104825784B (en) A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application
CN116211993B (en) Composition for treating senile chronic disease and its preparation method
CN102727624B (en) New application of enteritis peaching composition on treatment of chronic prostatitis
CN113599484A (en) Traditional Chinese medicine composition for treating pain and preparation method and application thereof
CN101129493B (en) Antineoplastic anti-AIDS pharmaceutical composition and method of preparing the same
CN1488385A (en) Chinese medicine composition for treating climacteric metancholia for women and preparing method thereof
CN108126134B (en) Traditional Chinese medicine compound composition for treating liver injury, preparation method and application thereof
CN100372546C (en) Chinese medicinal preparation for treating prostatitis and its preparation method
CN105943860A (en) Medicine preparation for treating diabetes mellitus and preparation method thereof
CN105535226A (en) Medicine composition for treating esophagus cancer and preparation method thereof
CN111759872A (en) Medicine for treating hypertension and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination